|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] K Porter, on behalf of CASCADE collaboration
MRC Clinical Trials Unit, London, UK
BHIVA Conf 2001 Apr 27-29;7:O1
OBJECTIVE: To examine whether an increase of 100 CD4 cells/µl following the initiation of highly active antiretroviral therapy (HAART) is influenced by the time interval since HIV seroconversion.
METHODS: We used logistic regression models, with a CD4 cell rise of at least 100 cells/µl in the 6-month period following HAART initiation as the outcome variable, on pooled data from 19 cohorts from Europe and Australia. All subjects had known or well-estimated times of HIV seroconversion. We examined the association of this CD4 cell response with the time interval since seroconversion to HAART initiation, adjusting for age at seroconversion; sex; exposure category; use of previous therapy; and CD4 cell count at HAART initiation.
RESULTS: Of 585 seroconverters starting HAART, 248 (42%) had an increase of at least 100 cells/µl within 6 months of initiation (overall median increase 88 cells/µl). In this cohort, 108, 150, 182 and 145 persons initiated HAART within 2 years, 2–5, 5–9 and over 9 years following seroconversion, respectively. Of these, 62, 66, 71 and 49 respectively, had a CD4 count rise of at least 100 cells/µl. We found no evidence to suggest that a CD4 rise of 100 cells/µl within 6 months of starting HAART was influenced by the duration of HIV infection. We also found that, compared with those who had been treatment-naïve at HAART initiation, prior use of therapy was significantly independently associated with a lower probability of the CD4 cell rise (odds ratio and 95% confidence intervals 0.37, 0.23–0.61; 0.46, 0.29– 0.75 for prior use of mono- and dual therapy, respectively).
CONCLUSIONS: Our results suggest that a CD4 rise of at least 100 cells/µl can be achieved within 6 months of starting potent antiretroviral therapy regardless of how long after infection it is initiated. Long-term follow-up is required to assess more durable response.
PRESENTING AUTHOR: K Porter
010427
O1
Copyright © 2001 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD